Laddar populära aktier...
Q2e: return to growth as comps ease For Q2, we expect sales of SEK 45m, up 10% y-o-y, marking a retu...
Redeye comments on the final outcome of Modelon’s rights issue, giving the company SEK50.
Cultural and customer similarities bode well Prevas has received regulatory clearance for its acquis...
Redeye comments on Genovis following the announcement of a strategic investment in SEQURNA, a develo...
Reasons to be optimistic after slow start to the year We expect Elanders to report Q2 net sales of S...
AAC Clyde Space has announced the acquisition of Spacemetric for a total consideration of SEK25m (in...
Förvaltningsresultat ökade med 26% på årsbasis drivet av främst ränteintäkter.
Duell’s Q3 development was two-fold as growth in Europe was stronger than expected while revenue dec...
Redeye comments on the Paxman contract with the US Veterans Association as a sole contractor with th...
Redeye comments on W5’s announcement of a major framework agreement for generators worth up to SEK50...
Redeye presents its preview for Devyser Diagnostics’ Q2 2024 report, due on July 23.
Redeye is encouraged by Nekkar’s acquisition of Globetech which was announced this morning.
Refine Group AB ("Refine", "Koncernen" eller "Bolaget") meddelade den 28 juni år 2024 att dotterbola...
Profitability below expectations Duell’s Q3 net sales came in at EUR 37.
Q2 preview: EBITA growth of 16% y-o-y In Q2, we expect easy growth comps to result in a sequential a...
